Integra Lifesciences Holdings Corporation · NASDAQ:IART
Integra Lifesciences — 2024 JP Morgan Healthcare Conference
17 slides from Integra Lifesciences's conference presentation, January 2024
Slide 1: 2024 Integra Lifesciences JP Morgan Healthcare Conference
2024 Integra Lifesciences JP Morgan Healthcare Conference 2024 JP Morgan Healthcare Conference | 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presenta tion contains forwa rd-looking s tatements wi thin the meaning of the Pri va te Securi ties Li ti gati on Reform Act of 1995 tha t invol ve risks and uncertainties and reflect the Company's judgment as of the da te of this presenta tion. All s tatements , other th
Slide 3: Integra Overview (NASDAQ: IART)
Integra Overview (NASDAQ: IART) Restoring Patients' Lives through Technologies that Transform Surgical, Neurologic & Regenerative Care C O D M A N S P E C I A LT Y S U R G I C A L TI SSUE TECHNOLOGI ES Transformative leader in Neuro -access, Regenerative Outcomes leader in complex -surgery, -monitor
Slide 4: Where We Play and How We Play
Where We Play and How We Play Mid-size Business, Leading Player in our Markets Through Focus O U R A D V A N TA G E D Specialty surgical, neurological and regenerative care POSITION TAM: ~$9B WAMGR: 5+% Unique focus and #1-2 player in attractive markets Neurosurgery & ENT and Complex Wound & Surgica
Slide 5: Codman Specialty Surgical Overview
Codman Specialty Surgical Overview Established Leadership in Served Markets, Portfolio Positioned to Exceed Market Growth >$1B Revenue1 >4% LRP CAGR2 N E U R O S U R G E R Y and E N T INSTRUMENTS MSD Market CAGR LSD Market CAGR BRAIN LESION SURGERY WITH TRAUMATIC BRAIN HYDROCEPHALUS ENT NEURO AND SP
Slide 6: Tissue Technologies Overview
Tissue Technologies Overview Leading Position with Extensive and Differentiated Portfolio Rooted in Clinical Evidence ~$0.5B Revenue1 >7% LRP CAGR2 COMPLEX WOUND AND SURGICAL RECONSTRUCTION P R I V AT E L A B E L HSD Market CAGR MSD Growth COMPLEX WOUNDS, BURNS, TRAUMATIC, SOFT TISSUE AND MUSCLE FLA
Slide 7: Driving an Integrated Growth Strategy
Driving an Integrated Growth Strategy Strengthening Operational Capability and Efficiency, Accelerating Innovation and Growth ENABLERS GROWTH DRIVERS DRIVE CULTIVATE BROADEN OPERATIONS A HIGH- INNOVATE FOR GROW IMPACT ON CARE AND CUSTOMER PERFORMANCE OUTCOMES INTERNATIONAL PATHWAYS EXCELLENCE CULTUR
Slide 8: Drive Operations and Customer Excellence
Drive Operations and Customer Excellence Building Global Scale, Efficiency and Resilience 2023 Accomplishments Sourcing Technology Delivery Customer Service Expanded Le Locle site, enabling launch of differentiated NPI’s Centers of Excellence Established ICFC1 manufacturing Global Centers of Excelle
Slide 9: Boston and Quality Management System Update
Boston and Quality Management System Update P R O G R E S S A N D M I L E S TO N E S L E A R N I NG S S H A R E D & I M P L E M E NT ED A C R O S S Interim external progress reviews T H E C O M PA N Y ✓ confirm adequacy of plan and execution Upgraded leadership Standardizing CAPA ✓ Factory restart N
Slide 10: Driving Gross Margin Improvement
Driving Gross Margin Improvement Operational efficiency opportunity assessment to Re-establish the Path to Sustainable Margin Improvement VA LU E C R E ATI O N L E V ER S HOW WE WILL GO A BOU T IT Volume / Mix / Price capture Operational efficiency • Reduce unplanned downtime, labor optimization • I
Slide 11: Cultivating a High-Performance Culture
Cultivating a High-Performance Culture Talent Philosophy Agile Organization • Talent Development Framework • Defined Cross-Functional Collaboration approach 2023 Accomplishments • Talent Attraction • Focus on Growth Drivers and Customers Awarded Great Place • Performance Management to Work in China
Slide 12: Innovate for Outcomes
Innovate for Outcomes Targeting Clinical and Economic Outcomes that Elevate the Standard of Care NEW CLINICAL INDICATIONS NEW SURGICAL APPROACHES INNOVATIVE PIPELINE1 2023 Accomplishments Relaunched CereLink in international markets ; submitted 510(k) for CereLink in the U.S. + Submitted clinical PM
Slide 13: Innovate for Outcomes
Innovate for Outcomes Accessing Accretive Growth Through Innovation INNOVA TIVE SOLUTION MARKET LONG-TERM P R O D U C TS SIZE O P P O R T U NI T Y • Advanced visualization in MIS • Today: $50M device market. • >$50M U.S. revenue by 2027 Aurora Surgiscope single instrument access (blood 2027: expandi
Slide 14: Grow International
Grow International Leveraging Global Footprint built for Growth in 130 Countries Geographic expansion in 2023 Accomplishments key emerging markets High single digit growth in United States Europe International markets1 $1.1B 1 $0.2B1 Portfolio leverage incl. CUSA Double-digit growth and DuraGen expa
Slide 15: Broaden Impact on Care Pathways
Broaden Impact on Care Pathways Increasing our Portfolio Depth while Extending along the Patient Journey 2023 Accomplishments Signed definitive agreement to acquire the Acclarent® ENT business Successful commercial and clinical integration of Surgery Planning Strengthen Site of Care SIA acquisition
Slide 16: Committed to Value Creation
Committed to Value Creation Near-term investments for long-term profitable growth acceleration Strengthening market leading positions in attractive markets COMMUNICATION PLAN Investing in growth accretive segments & portfolio Next update: Q4 2023 Results & 2024 Guidance February 28, 2024 Globally ex
Slide 17: Key Takeaways
Key Takeaways Strong Commercial and Portfolio Foundation, with an Operational, Innovation and In-organic path to achieve LRP targets 1 2 3 Global Leader in neurosurgery, and Strengthening operations and Expanding our reach in care regenerative technologies. quality capabilities to accelerate pathway
Integra LifeSciences Holdings — 2024 JP Morgan Healthcare Conference on 6ix